In May 2024, ivonescimab in combination with pemetrexed and carboplatin received its first approval in China for the treatment of EGFR-mutant locally advanced or metastatic non-squamous NSCLC following EGFR-TKI progression (24). Here, EGFR is linked to non-small cell lung carcinoma.